Together, animal studies and observations in women provide a strong case for a causative role for AP activation in adverse pregnancy outcomes in APS, and provide a strong rationale for clinical evaluation of AP inhibitors, at least in refractory APS if not in all APS pregnancies. The gene discussed is DHCR7-DT; the disease is autoimmune polyendocrinopathy.